Biyopharma Secures Tens of Millions in RMB in Angel Funding Led by Transfar Capital and Tailong Investment

Recently, Hangzhou Baiyi Biopharmaceutical Co., Ltd. announced the successful completion of its angel financing round, raising tens of millions of RMB. The round was co-led by Transfar Capital and TAILONG VC, with Triwise Capital participating as a follow-on investor. The funds raised will be primarily used to accelerate the research and development of the company’s two innovative migraine drugs and to file Investigational New Drug (IND) applications.

BIOPHARMA, established in 2021, is dedicated to the research and development of innovative drugs for neurological disorders. The company’s founding team brings over two decades of industry experience and has built multiple technology platforms at an international level. BIOPHARMA is committed to providing better solutions for difficult-to-treat conditions such as episodic migraine and chronic migraine.

Transfar Capital is deeply rooted in industry, placing strong emphasis on industrial chain layout and the construction of a sci-tech innovation ecosystem. Adhering to the investment philosophies of “value investing,” “research-driven decision-making,” and “ecosystem empowerment,” it aims to serve portfolio companies, empower partners, and leverage capital as an engine to connect the value chains of sci-tech innovation and industry. By fully leveraging Transfar Group’s robust industrial foundation and the dynamic sci-tech innovation ecosystem of Transfar Sci-Tech City, Transfar Capital strives to set a benchmark for developing new quality productive forces in Hangzhou, Zhejiang. Its managed funds cover innovation incubation, venture capital (VC), private equity (PE), mergers and acquisitions (M&A), and funds of funds (FOF), forming a comprehensive capital ecosystem that supports projects throughout their entire lifecycle, with assets under management exceeding RMB 10 billion.

The Transfar Life Sciences Fund, which participated in this investment, is a venture capital fund focused on the life sciences sector. Initiated and established by Transfar Science & Technology City, the fund has an initial size of RMB 500 million. It primarily targets early-stage projects, focusing on four key sub-sectors: synthetic biology, advanced therapies and new drugs with clinical value, innovative medical devices, and high-value consumables. Adhering to the EVC (Ecosystem Venture Capital) investment philosophy, the fund collaborates with external market-oriented funds, corporate venture capital (CVC) firms, and government investment platforms to help Transfar Science & Technology City build a premier international biotechnology innovation hub that attracts talent, technology, and capital. To date, the fund has invested in more than 10 high-potential biotechnology companies, including Lingyi Biologics, Guiyi Technology, Rongrui Technology, Derui Zhiyao, Shentuo Biology, and Yimuhe Biology.

TAILONG VC was established in 2021 as a professional equity investment management firm specializing in biopharmaceuticals, medical devices, and the broader healthcare sector. It manages the Taikun Fund, which has a scale of RMB 20 billion. TAILONG VC boasts a professional and seasoned investment team, focusing on biopharmaceuticals, innovative medical devices, core CXO services and emerging sectors, as well as leading biopharmaceutical industry funds. The firm is committed to building a science-driven, cross-cycle value investment platform for the biopharmaceutical industry.

Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (P1030072), established in October 2015, brings together senior executives from renowned venture capital firms such as Shenzhen Capital Group, industry veterans from Roche, GSK, BMS, AbbVie, AstraZeneca, Fosun Health, and BGI LifeTech, as well as scientific experts from prestigious academic institutions both in China and abroad. Guided by the philosophy of “redirecting investment toward the real economy and leveraging capital to serve industrial development,” Triwise Capital strategically layouts its industrial ecosystem, emphasizing original and value-based investing. By leveraging resources from industrial and technological platforms such as the National Innovation Center for High-Performance Medical Devices, the Institute of Synthetic Biology at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, and the Shenzhen Jiyin Institute for Biomedical Translation, the firm focuses on investments in cutting-edge fields including innovative drugs, synthetic biology, and high-end medical devices. It partners with industrial teams to “co-found ventures,” utilizing capital to facilitate the commercialization of scientific achievements. Its investment portfolio includes Akeso (09926.HK), Transwarp (688031.SH), Yuhang Therapeutics (688176.SH), Quanxin Biologics (02509.HK), ImmuneOnco Biopharmaceuticals, Fibio Biologics, and Northcore Life Sciences.